论文部分内容阅读
目的总结分析替格瑞洛与氯吡格雷在急性冠状动脉综合征(ACS)中抗血小板聚集的作用。方法 80例ACS患者,根据用药差异分为替格瑞洛组(给予替格瑞洛治疗)与氯吡格雷组(给予氯吡格雷治疗),各40例,观察比较两组患者治疗前后血小板聚集率以及不良心血管事件、不良反应情况。结果替格瑞洛组用药24 h、7 d、30 d时血小板聚集率均明显低于氯吡格雷组,组间差异具有统计学意义(P<0.05)。替格瑞洛组不良心血管事件发生率10.00%、不良反应率20.00%虽低于氯吡格雷组15.00%、25.00%,但差异无统计学意义(P>0.05)。结论在ACS治疗中,替格瑞洛抗血小板聚集效果更佳,值得推广使用。
Objective To summarize the effect of ticagrelor and clopidogrel on platelet aggregation in acute coronary syndrome (ACS). Methods Eighty patients with ACS were divided into ticagrelor group (given ticagrelor group) and clopidogrel group (given clopidogrel group) according to the difference of drug use, 40 cases in each group. The platelet aggregation Rates and adverse cardiovascular events, adverse reactions. Results The platelet aggregation rate of ticagrelor group was significantly lower than that of clopidogrel group at 24 h, 7 d and 30 d (P <0.05). The incidence of adverse cardiovascular events in the ticagrelor group was 10.00%, and the adverse reaction rate was 20.00%, which was lower than that in the clopidogrel group (15.00%, 25.00%). However, the difference was not statistically significant (P> 0.05). Conclusion In the treatment of ACS, ticagrelor is more effective in preventing platelet aggregation and is worth promoting.